Q1 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
1
GROWTH
Positive leading indicators for Pluvicto™ US launch
Strong benefit/risk profile reflected in label
Population: PSMA+ mCRPC patients
post ARPI and taxane1
Patient selection: Using LocametzⓇ
or other approved 68Ga-PSMA-11 agent¹
Clinical benefit: 38% reduction in
risk of death vs. SOC alone¹
Administration: Up to 6 infusions, 6 weeks apart¹
CE PZ K KL
PLUVICTO
US launch building on LutatheraⓇ experience
Commercial field teams trained
on promotional materials <5 days
High awareness among ~240 target RLT treatment
centers (existing LutatheraⓇ sites)
96% of RLT centers have product purchase
agreements in place
>40 RLT centers onboarded to ordering system; first
patients infused in April
☑ CMS applications submitted for permanent A code,
expected to be effective in October
EU approval anticipated in H2 2022. Additional Ph3 studies ongoing in pre-taxane and hormone sensitive settings, with
potential to expand patient population for Pluvicto™ 3-4x. Evaluating additional Ph3 studies.
1. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2022.
15 Investor Relations | Q1 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation